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Abstract
Regenerative medicine is a new therapeutic modality that aims to mend tissue damage by 
encouraging the reconstitution of physiological integrity. It represents an advancement 
over conventional therapies that allow reducing the damage but result in disease 
chronicization. Age-related decline in spontaneous capacity of repair, especially in organs 
like the heart that have very limited proliferative capacity, contributes in reducing the 
benefit of conventional therapy. ncRNAs are emerging as key epigenetic regulators of 
cardiovascular regeneration. Inhibition or replacement of miRNAs may offer reparative 
solutions to cardiovascular disease. The first part of this review article is devoted to 
illustrating novel therapies emerging from research on miRNAs. In the second part, 
we develop new therapeutic concepts emerging from genetics of longevity. Prolonged 
survival, as in supercentenarians, denotes an exceptional capacity to repair and cope 
with risk factors and diseases. These characteristics are shared with offspring, suggesting 
that the regenerative phenotype is heritable. New evidence indicates that genetic traits 
responsible for prolongation of health span in humans can be passed to and benefit 
the outcomes of animal models of cardiovascular disease. Genetic studies have also 
focused on determinants of accelerated senescence and related druggable targets. 
Evolutionary genetics assessing the genetic basis of adaptation and comparing successful 
and unsuccessful genetic changes in response to selection within populations represent 
a powerful basis to develop novel therapies aiming to prolong cardiovascular and whole 
organism health. 
Introduction
The number and proportion of older people is growing in 
every country in the world. According to data from World 
Population Prospects (2019 Revision), by 2050, 16% of the 
people in the world will be over age 65, almost doubling 
the figure in 2019; and the number of persons aged 80 
years or over is projected to triple. In Europe and Northern 
America, the proportion of 65 or over is forecasted to 
be 25% by 2050. This demographic transformation has 
remarkable social implications, including work, markets, 
request, and availability of services such as housing, health, 
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and mobility. Prolongation of lifespan correlates with an 
increased number of individuals with chronic pathologies 
often requiring hospitalization. Many countries are 
already facing problems related to the impact of the 
aging population on the national health system, pension 
schemes, and social protections. Specific actions on health 
and nutrition, protecting elderly people, housing and 
environment, family, and social/medical welfare are in the 
agenda of policy makers and governmental agencies.
All around the world, scientists are trying to beat 
age-related diseases, such as heart attacks, cancer, and 
dementia; stop people getting ill is an obvious goal to aid 
the individual wellbeing and reduce pressure on society. 
At the whole organism level, aging has been defined as the 
time-related deterioration of the physiological functions 
necessary for survival and fertility. This definition applies 
to all the individuals of a species and overlaps with 
disease-related aging. Aging of the vasculature plays a 
key role in morbidity and mortality of older people. It 
is often assimilated with endothelial dysfunction, that 
is, the failure of vascular endothelial cells to respond to 
vasoactive stimuli and mount reparative transformation 
upon tissue damage. Zooming into the molecular level, 
aging of the vasculature consists in small, incremental 
amounts of damage that spreads to all vascular cells, 
including vascular smooth muscle cells and pericytes, and, 
owing to the system dependency on vascular homeostasis, 
to tissues and organs; eventually, the whole organism will 
suffer from this accumulation of damage. 
In this article, we focus on molecular therapies 
that can aid an organism to correct deviations from or 
maintain physiological homeostasis. Two specific fields 
are considered. A review of recent research on ncRNAs and 
new genetic approaches inspired by extreme longevity 
aims to prolong health-span. 
Mechanisms of vascular aging
The development of novel treatments targeting vascular 
aging and prevention of age-related vascular pathologies 
requires a better knowledge of the cellular and functional 
changes that occur in the vasculature during aging. These 
include oxidative stress, mitochondrial dysfunction, 
susceptibility to molecular stressors, chronic low-grade 
inflammation, genomic instability, cellular senescence, 
epigenetic alterations, loss of proteostasis, deregulated 
nutrient sensing, and stem cell dysfunction. Senescent 
cells secrete autocrine or paracrine factors, including 
cytokines, growth factors, proteases, and soluble receptors 
called senescence-associated secretory phenotype (SASP) 
(1). One dominant SASP molecule is the monocyte 
chemoattractant potein-1 (MCP-1/CCL2) which acts 
through binding to cognate receptor CCR2. Hence, MCP-1 
could be exploited as a marker of cell senescence both 
in vitro and in vivo. Review articles and commentaries have 
been published on this topic in recent years (2, 3, 4, 5, 6).
The capacity to repair and regenerate empowers 
living organisms with resilience to natural fluctuations 
and events that cause disturbance or damage. Aging and 
regeneration are two sides of the same coin and this has 
been confirmed through the examination of species with 
extreme regenerative capabilities, such as planarians and 
salamanders, which show no signs of aging or quantifiable 
age-associated functional decline (7). In contrast, in 
complex organisms like humans, aging is characterized 
by a decay in the regenerative capacity and reparative 
activities (8). Tissue-specific stem cells and progenitor cells 
incur in age-related defects, such as the loss of self-renewal 
capacities and proliferative activity and the deterioration 
in functionality and potency (9). Likewise, differentiated 
cells become progressively uncapable of regulating 
protein synthesis and metabolism, especially under stress 
conditions, eventually undergoing irreversible proteotoxic 
damage (10). Exhaustion of compensatory mechanisms 
increases the susceptibility to risk factors and diseases and 
results in excess morbidity and mortality. 
miRNAs involved in aging and regeneration
The first part of this review article is dedicated to the 
emerging role of miRNA in aging and regeneration. 
ncRNAs and among these several miRNAs genes can be 
epigenetically regulated by DNA methylation and/or 
histone modifications. In addition, a subgroup of miRNAs, 
named epi-miRNAs, directly target enzymatic effectors 
involved in epigenetic modulation (11). Therefore, a 
regulatory loop between epigenetic modulation and 
miRNAs does exist, which could significantly affect 
transcription and enhance or slow-down aging and 
age-related diseases (11). The following miRNAs are 
either epigenetically regulated or represent epi-miRNAs 
involved in aging and in cardiovascular regeneration and 
are summarized in Fig. 1.
The miRNA-200 family
The miRNA-200 family consists of five members (i.e. 
miRNA-200a, miRNA-200b, miRNA-200c, miRNA-141, 
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and miRNA-429). MiRNA-200 plays a major role in the 
epigenetic control of tumorigenesis and Epithelial to 
Mesenchymal transition (EMT) (12). A negative feedback 
loop between miRNA-200c and DNA methyltransferase 
3a (DNMT3a) was shown in gastric cancer cells (13). 
miRNA-200b has been shown to target Suz12, a subunit 
of polycomb repressive complex 2 (PCR2) decreasing 
H3 lysine 27 trimethylation at the promoters of target 
of E-cadherin, thereby causing transcriptional increase 
(14). The interaction between miRNA-200 and Suz12 is 
highly conserved, and it seems to represent a regulatory 
mechanism to control the growth and function of 
stem cells.
miRNA-200 upregulation has been linked to aging. 
In particular, miRNA-200c and miR-141 expressions are 
increased in skeletal muscles and arteries of aging rhesus 
monkeys and mice (15, 16). miRNA-141 and miRNA-200c 
increase with aging in human liver (17). In addition, 
miRNA-200a was found upregulated in primary human 
keratinocytes from aging individuals (18). miRNA-200 
upregulation with aging contributes to the impairment 
of mechanisms implicated in the repair of oxidative 
DNA damage in keratinocytes and endothelial cells 
(18, 19, 20). The most expressed and induced member, 
miRNA-200c, is responsible for apoptosis and senescence 
via downregulation of the transcription factor ZEB1 
and a p53 and pRb-dependent mechanism (20). 
Moreover, miRNA-200c upregulation induces endothelial 
dysfunction, since it disrupts the autoregulatory loop 
among three important proteins for endothelial function: 
Sirtuin 1 (SIRT1), forkhead box O1 (FOXO1), and the 
endothelial nitric oxide synthase (eNOS), directly 
targeting all of them (16). SIRT1 is a major regulator of 
longevity and metabolic disorders (21). Its downregulation 
by miRNA-200c results in increased levels of acetylation 
of both p53 and FOXO1. Acetylated p53 is more active 
and further induces miRNA-200c. FOXO1 acetylation 
inhibits its transcriptional activity, with the consequent 
decrease of catalase and Manganese Superoxide dismutase 
(MnSOD or SOD2), two ROS-scavengers, finally leading 
to oxidative stress upregulation (16). In addition, SIRT1 
deacetylates eNOS increasing NO bioavailability, while 
NO stabilizes the mRNA and protein of SIRT1 (22). Since 
miRNA-200c targets both eNOS and FOXO1, their decrease 
further contributes to the disruption of the autoregulatory 
loop inducing endothelial dysfunction (16).
miRNA-200c also plays a major role in cardiovascular 
diseases (19). miRNA-200c is upregulated in plaques 
and plasma of atherosclerotic patients, being further 
enhanced in unstable vs stable carotid plaques (23) and 
in plasma of children with familiar hypercholesterolemia 
(24). miRNA-200c was found upregulated in 
cardiomyopathies induced by doxorubicin (DOX) 
in mice as well as in human cardiac mesenchymal 
progenitor cells exposed to DOX (25). Interestingly, 
stromal cell-derived factor-1 (SDF-1) administration 
was able to partially revert DOX-induced miRNA-200c 
and p53 protein upregulation in mouse hearts, and to 
revert both the adverse remodelling and the impaired 
ventricular function (25). In addition, miRNA-200c 
is induced following acute hindlimb ischemia in mice 
(16, 20). Inhibition with antimiRNA-200c increased post-
ischemia reperfusion and reparative angiogenesis (16). 
Likewise, miRNA-200c inhibition restored endothelial 
function in diabetes (26) and attenuated cardiomyocyte 
hypertrophy in high glucose-treated cardiomyocytes (27).
miRNA-141 is involved in mitochondrial dysfunction 
and in cardiac abnormalities associated with type 1 
diabetes (28). It targets the solute carrier family 25 
member 3 (SLC25A3), an inner mitochondrial membrane 
phosphate transporter, which is essential for ATP 
production since it provides inorganic phosphate to the 
mitochondrial matrix. SLC25A3 expression is decreased 
in type 1 diabetes, which has a deleterious effect on 
ATP production and cell viability (28). Interestingly, 
miRNA-141 also targets ZMPSTE24, which is involved 
in the post-translational maturation of lamin A (29). 
Figure 1
Biological effects of Epi-miRNAs.
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ZMPSTE24 is responsible for the prelamin A accumulation 
in cellular senescence of human mesenchymal stem cells 
isolated from umbilical cord blood. Moreover, miRNA-141 
is upregulated during senescence as a result of epigenetic 
regulation of its promoter region (29).
Altogether, these data indicate that miRNA-200 
is deeply involved in the epigenetic control of aging 
and regeneration in different tissues and cells. Its 
manipulation can have beneficial effects on vascular and 
cardiac function.
The miRNA-34 family
The miRNA-34 family consists of three highly homologous 
miRNAs, miRNA-34a, b, and c. It is often epigenetically 
regulated in different diseases and tumors (30). A 
miRNA-34a activation has been associated with ethanol-
linked hypomethylation of the miRNA-34a promoter 
(31). The miRNA-34a promoter is hypomethylated in 
preeclamptic placentas (32), and, in cholangiocarcinoma, 
miRNA-34a expression is silenced epigenetically by EZH2 
and DNA methylation (33). In addition, miRNA-34a 
regulates epigenetic enzymes, such as deacetylases SIRT1 
and HDAC1 (34, 35).
This miRNA family exhibits an age-dependent 
increase in different murine tissues, including liver, heart, 
and brain (36), in rat endothelial progenitor cells (37), and 
in human vasculature. miRNA-34a is thought to play an 
important pathogenic role in vascular smooth muscle cells 
senescence, calcification, and plaque formation through 
downregulation of SIRT1 and AXL Receptor Tyrosine 
Kinase (38, 39). Accordingly, murine vascular smooth 
muscle cells lacking miRNA-34a are resistant to develop 
senescence and calcification (39). Experimental studies 
using anti-miRNA-34a in high fat diet (HFD)-induced 
ApoE-/- mice showed reductions in atherosclerotic lesions 
and vascular cells apoptosis. Likewise, anti-miRNA-34a 
promoted cell viability and restrained apoptosis in 
ox-LDL-treated human aortic endothelial cells (40) and 
induced proliferation in human cardiac progenitor 
cells (41).
miRNA-34a has been associated to heart failure, where 
upregulation in cardiomyocytes targets pro-proliferative 
and pro-survival proteins CyclinD1 and Bcl2 (42). 
Several days post-MI, older mice exhibited a significant 
increase of miRNA-34a expression compared to young 
mice, resulting in a decline of cardiac performances and 
cardiac remodeling. Inhibition of either miRNA-34a 
or of the entire miRNA-34 family improves cardiac 
function in terms of fibrosis, cardiac remodeling, and 
cardiomyocyte death in models of myocardial infarct 
(42). Higher miRNA-34a levels have been found in 
diabetes; in particular, miRNA-34a is elevated in plasma 
of diabetic patients and is upregulated in cardiac 
progenitor cells and cardiomyocytes exposed to high 
glucose, suggesting an inductive role of senescence in 
the diabetic heart (43).
miRNA-34 has been associated with reduction of 
lifespan. Interestingly, miRNA-34 is upregulated during 
C. elegans aging where it appears to antagonize longevity 
by repressing the autophagy gene atg9 (44). In Drosophila, 
miRNA-34 has been shown to be essential for normal 
aging. Loss-of-function mutants of miRNA-34 display 
shorter lifespan through EIP74, an ecdysone-induced 
transcription factor (45).
In summary the miRNA-34 family plays a pivotal role 
in the epigenetic control of lifespan and is pathogenically 
involved in atherosclerosis, vascular calcification, cardiac 
fibrosis, and adverse remodeling in heart failure. Its 
inhibition can improve cardiovascular repair.
miRNA-21
miR-21 is epigenetically regulated in ovarian cancer 
and colorectal cancer (46, 47). miRNA-21 expression 
increases with aging in murine hearts and plays a major 
role in cardiac fibrosis in mice and in patients with aortic 
stenosis (48, 49). In a mouse model of acute cardiac 
allograft transplantation, it activates mitogen-activated 
protein kinase (MAPK) signaling in fibroblasts inducing 
cardiac fibrosis (50). Suppression of miRNA-21 prevents 
cardiomyocyte senescence induced by d-galactose and 
DOX (51) and promotes angiogenesis by restoring Ras 
homolog family member B (52).
The miRNA-29 family
The miRNA-29 family consists of three members, miRNA-
29a, miRNA-29b, and miRNA-29c. It acts as a regulator of 
cell survival by inducing global DNA hypomethylation. It 
has been shown to directly target DNA methyltransferases 
DNMT-3A and DNMT-3B in lung cancer (53) and indirectly 
DNA methyl transferase DNMT1 through the regulation 
of the trans-activator Sp1 in leukemia (54).
miRNA-29 is upregulated in aging hearts and its 
dysregulation after myocardial infarction induces the 
activation of TGFB causing cardiac fibrosis (55). MiRNA-29b 
administration inhibits TGFb/Smad3 signaling in 
hypertensive rats preventing cardiac fibrosis (56). An 
inverse correlation of circulating miRNA-29a with cardiac 
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fibrosis has been found in the plasma of patients with 
cardiac hypertrophy (57).
miRNA-29 modulates vascular function, as 
demonstrated by studies in diabetic models, in which 
intraluminal delivery of miRNA-29a or miRNA-29b 
restored normal endothelium-dependent vasodilation 
increasing NO availability. Thus, miRNA mimics may have 
therapeutic potential for cardiometabolic disorders (58). 
Interestingly, another miRNA-29 target is the prelamin A 
interacting protein (59). miRNA-29 is induced in a model 
of HGP syndrome, the Zmpste24-deficient mice, reflecting 
a p53-dependent compensatory response to DNA damage 
(59). miRNA-29 targets Ppm1d phosphatase, which in 
turn enhances p53 activity, inducing further miRNA-29 
upregulation and eventually decreasing cell survival and 
proliferation (59).
miRNA-101
miRNA-101 is an epi-miRNA that targets both EZH2 
(60) and EED (61), two pivotal components of histone 
methyltransferase PCR2 complex, involved in cell 
proliferation and differentiation. Moreover, miRNA-101 
increases with aging in brain (62). Following coronary 
artery ligation, miRNA-101 levels are downregulated 
in both rat cardiac fibroblasts and myocytes. MiRNA-
101 overexpression inhibits fibrosis and adverse cardiac 
remodelling through inhibition of c-FOS, a transcriptional 
modulator of TGFb (63). In a rat model of hypertrophy, 
miRNA-101 overexpression inhibited cardiomyocytes 
hypertrophy through the downregulation of its target small 
GTPase Rab1a (64). Finally, miRNA-101 is downregulated 
upon VEGF treatment, resulting in increased expression 
of the histone methyltransferase EZH2 in endothelial cells 
and promotion of angiogenesis (65).
In summary, miRNA-101 modulates epigenetic and 
cardiovascular homeostasis, although its modulation with 
aging in cardiovascular tissues remains unexplored.
Noncoding RNAs that sponge miRNAs 
involved in aging and regeneration
In the last decades, other ncRNAs, such as long ncRNAs 
(lncRNAs) and circular RNAs (circRNAs), have been 
discovered and attracting attention in research. LncRNAs 
are ncRNAs that are 200 nt longer, usually polyadenylated, 
capped, and spliced (66). LncRNAs are transcribed from 
different genomic regions, such as intergenic regions, 
promoter upstream regions, enhancers, and the opposite 
strand of protein-coding genes. Some lncRNAs are 
generated by unique biogenesis, such as RNase P cleavage 
and capping by snoRNA-protein (snoRNP) complexes at 
their ends (67).
CircRNAs are ncRNAs characterized by a covalently 
closed continuous loop without polarity or a 
polyadenylated tail (68). CircRNAs usually originate 
from protein-coding genes and complete exons (69) 
and are mainly produced during splicing. CircRNAs are 
resistant to exonucleases due to lack of free ends. They 
also have potential to roll circle amplification, constrain 
RNA folding, and rearrange genomic sequences (70). The 
most important function of circRNAs is miRNA sponge, 
where they regulate miRNAs. However, it is shown 
previously that some circRNAs are translated into 
polypeptides (69, 71).
Here we will discuss relevant lncRNAs and circRNAs 
known to sponge relevant miRNAs described previously 
that are known to have a role in cardiovascular aging and/
or regeneration (Table 1).
Long noncoding RNAs (lncRNAs) and circular RNAs 
(circRNAs) that sponge miRNA-200 family
lncRNA MALAT1 (metastasis associated lung 
adenocarcinoma transcript 1) has been associated to 
miR-200 family in different studies related with cancers (72, 
73, 74). Interestingly, its modulation has also been linked 
to CVD. Higher expression of MALAT1 was observed in 
both humans and rodents with MI, myocardial ischemia-
reperfusion injury, and cardiomyocytes of arrhythmic 
rats (75, 76).
The role of MALAT1 in miR-200c/HMGB1 pathway 
was studied in arrhythmic rat model and shows that high-
mobility group box 1 (HMGB1) acts as a downstream 
target of miR-200 family. miR-200 family inhibits HMGB1 
expression at both mRNA and protein levels. MALAT1 
sponges miR-200c causing HMGB1 upregulation and 
thereby downregulating cardiac transient outward 
potassium current (Ito) associated arrhythmia (76). 
Further, in mice undergoing coronary artery ligation 
to produce acute MI, exogenous HMGB1 has been 
shown to promote cardiac repair, to improve cardiac 
function (77), and to inhibit adverse remodeling via an 
increase in miR-206 that directly targets Tissue Inhibitor 
of Metalloproteinase–3 (TIMP3) (78). Knockdown of 
MALAT1 or overexpression of miR-200c reduces HMGB1 
expression level, indicating that MALAT1 sponges miR-
200c to promote HMGB1 expression. Moreover, MALAT1 
modulates outward potassium and repolarization currents 
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that are involved in myocardial function. In hypoxia-
induced cardiomyocytes, MALAT1 sponges miR-200a and 
upregulates programmed cell death 4 (PDCD4) expression, 
indicating that MALAT1-miR-200a-PDCD4 axis regulates 
cell cycle progression, proliferation, and apoptosis in 
myocardial cells (79).
LncRNAs and circRNAs that sponge miRNA-141
Several studies have shown the interaction of miR-141 
with lncRNAs in different diseases including cancers 
(80, 81, 82). However, only few studies are available on 
lncRNAs and circRNAs that sponge miR-141 in CVD. 
Among these circRNA_010567 is a fibrosis-promoting 
RNA upregulated in myocardium of diabetic mice and in 
cardiac fibroblasts (CFs) treated with Ang II (83). In db/db 
mice model, it was found that circRNA_010567 directly 
binds to miR-141. Indeed, silencing of circRNA_010567 
results in upregulation of miR-141 and downregulation 
of its target TGF-b1, thereby causing the suppression of 
fibrosis associated protein resection in cardiac fibroblasts. 
This indicates that circRNA_010567/miR-141/TGF-β1 axis 
plays a major role in myocardial fibrosis (83).
LncRNAs and circRNAs that sponge miRNA-34 family
Maternally expressed gene 3 (MEG3) is a highly expressed 
lncRNA associated with myocardial infarction, transverse 
aortic constriction (TAC), and cardiac hypertrophy 
(84, 85). It contributes to endothelial dysfunction by 
mediating epigenetic regulations in aging (86). MEG3 
inhibition in cardiac fibroblasts prevents cardiac fibrosis 
and improves diastolic performance (87). miR-34a is a 
direct target of MEG3 (88). In vivo studies on hepatocyte 
ischemia-reperfusion (HIR) injury revealed that MEG3 
functions as a competing endogenous RNA for miR-34a. 
It downregulates miR-34a expression and protects 
hepatocytes from HIR injury mediated through 34a/Nrf2 
signaling pathway (89). Further, in diabetic retinopathy, 
MEG3 targets miR-34a/SIRT1 axis and alleviates high 
glucose inducing apoptosis, as well as inflammation by 
inhibiting the NF-κB signaling pathway (88).
Another lncRNA that shows a role in coronary artery 
disease (CAD) is C2dat1. LncRNA C2dat1 is a CaMK2D-
associated transcript 1. LncRNA shows higher expression 
in CAD (90). C2dat1 binds to miR-34a and modulates its 
expression in CAD. Overexpression of C2dat1 suppresses 
miR-34a expression and upregulates its target protein 
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LncRNA HOX transcript antisense RNA (HOTAIR) 
is a highly conserved and abundant lncRNA associated 
with various essential biological processes involved in 
different diseases. Increased expression of HOTAIR was 
observed in both plasma and cardiac tissues of patients 
with cardiac hypertrophy (92, 93). In contrast, diabetic 
mice showed a significant decrease in the expression of 
HOTAIR in heart tissues. HOTAIR knockdown in H9C2 
rat cardiomyoblast cell line resulted in an elevated 
oxidative injury, inflammation, and apoptosis, whereas 
HOTAIR overexpression attenuated myocyte death and 
improved cardiac function. HOTAIR, in fact, functions 
as a competing endogenous RNA (ceRNA) of miR-34a. It 
has been demonstrated that HOTAIR sponges miR-34a, 
causing upregulation of SIRT1 expression and protecting 
mice from diabetic cardiomyopathy (94).
LincRNA 1700020I14Rik is another lncRNA that 
regulates miR-34a-5p/Sirt1/HIF-1α signaling pathway 
by inhibiting cell proliferation, as well as fibrosis in 
diabetic nephropathy. Under elevated glucose condition, 
overexpression of lncRNA 1700020I14Rik prevents the 
expression of renal fibrosis markers and decreases cell 
proliferation, whereas its downregulation produces the 
opposite effect (95).
Although no studies have been published on 
LincRNA 1700020I14Rik and the heart and blood vessels, 
these observations raise the possibility of a link between 
LincRNA 1700020I14Rik and cardiovascular disease in 
diabetic patients with renal failure.
LncRNAs and circRNAs that sponge miRNA-21
miR-21 is a highly expressed microRNA in the 
cardiovascular system; it attenuates inflammation, 
maladaptive remodeling, and cardiac dysfunction in post 
myocardial infarction (96). Recent studies have reported 
that miR-21 expression can be modulated by other ncRNA 
associated with various molecular pathways (97).
TALNEC2 is a E2F1-regulated putative lncRNA, also 
known as Tumor Associated Long ncRNA Expressed 
on Chromosome 2. High expression of TALNEC2 was 
observed in myocardial ischemic patients. Studies on 
H9c2 cells showed that TALNEC2 modulates miR-21 
expression under hypoxic condition. Overexpression of 
TALNEC2 aggravates hypoxic injury by downregulating 
miR-21 via the regulation of miR-21/PDCD4-mediated 
activation of the Wnt/β-catenin signaling pathway in 
myocardial ischemic injury (98).
Long ncRNA taurine upregulated gene 1, also known 
as lncRNA TUG1, is known to promote VSMC proliferation 
and to induce atherosclerosis progression. High expression 
of TUG1 was observed in atherosclerosis and hypoxia (99, 
100). LncRNA TUG1 overexpression induces endothelial 
cell apoptosis, and its knockdown decreases apoptotic 
ratio and promotes cell survival (101). Further, LncRNA 
TUG1 competes with phosphatase and tensin homolg 
(PTEN) for miR- 21 binding. Downregulation of TUG1 
markedly inhibit the expression of miRNA-21, indicating 
that lncRNA TUG1 promotes VSMC proliferation and 
atherosclerosis by regulating miRNA-21/PTEN axis 
(99, 100).
LncRNA MEG3, as described previously, is a vastly 
expressed lncRNA associated with CVD (84, 85). In 
contrast, some studies showed the reduced expression of 
lncRNA MEG3 in CVD and Hypoxia-induced pulmonary 
hypertension (97, 102). It has been shown that miR-21 is 
a direct target of MEG3. In CAD, MEG3 is downregulated 
and negatively correlates with miR-21 levels. MEG3 
overexpression suppresses EC proliferation and migration 
and reduces the expression of proteoglycan, type I, and 
V collagen through the decrease of miR-21 (102). Its 
inhibition promotes cell proliferation and migration in 
normal and hypoxic conditions through the miR-21/PTEN 
axis. Under hypoxic condition, MEG3 binds miR-21 and 
modulates PTEN expression resulting in cell proliferation 
and migration in pulmonary arterial smooth muscle cells 
(PASMCs) (97).
TCONS_00024652 is an endothelium-associated 
lncRNA involved in plaque angiogenesis and atherosclerosis 
progression. High expression of TCONS_00024652 was 
observed in TNF-α-stimulated HUVECs. The interaction of 
miR-21 with lncRNA TCONS_00024652 was determined 
using bioinformatics and molecular techniques. TNF-
α treatment increases TCONS_00024652 expression in 
a dose dependent manner, and its knockdown inhibits 
proliferation and angiogenesis in endothelial cells. 
Binding of miR-21 to TCONS_00024652 reduces its 
expression and may be a potential method of improving 
endothelial dysfunction and plaque stabilization (103).
LncRNAs and circRNAs that sponge miRNA-29 family
Long ncRNA H19 is a paternally imprinted gene located 
on chromosome 11p15.5. Several studies reported the 
significant increase of lncRNA H19 in various human 
cancers associated with tumorigenesis and metastasis 
(104). The lncRNA H19 directly binds to miR-29b-3p 
and lowers the expression of DNA Methyltransferase 3 
Beta (DNMT3B) epigenetic enzyme (105). Interestingly, 
LncRNA H19 has been reported to be upregulated in 
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atherosclerotic patients and to cause the increase of 
acid phosphatase 5 gene (106). The latter encodes a 
metalloenzyme named tartrate-resistant acid phosphatase 
(TRAP) that is significantly associated with cancer 
progression, and it is known to induce endothelial and 
VSMC proliferation and suppress apoptosis (107).
Although a direct link of RNA H19 and miR-29 family 
has not been described in CVD, it is possible that their 
association may modulate atherosclerosis progression. 
LncRNAs and circRNAs that sponge miRNA-101
X-inactive specific transcript (XIST) is a lncRNA that 
regulates cardiac hypertrophy. Significantly upregulated 
expression of lncRNA XIST was observed in hypertrophic 
mouse heart, postmyocardial infarction cells, as well 
as in H9c2 cells treated with phenylephrine (PE) (108). 
Recently, it was shown that XIST competitively binds to 
miR-101 and promotes cardiac hypertrophy by enhancing 
the expression of Toll-like receptor 2 (TLR2) (108).
Further, in gastric and esophageal squamous 
cell carcinoma, lncRNA XIST modulates epigenetic 
mechanisms through the regulation of miR-101/EZH2 
pathway causing cancer (109, 110).
Genetics of extreme longevity: can this 
inform new therapy sustaining health-span?
Although prolonged lifespan does not always correspond 
to health span, extreme longevity is often accompanied by 
reduced or delayed morbidity (111, 112). This led to the 
hypothesis that the aging-related decay is neither necessary 
nor irreversible (111). Genetic association investigation 
identified several candidate gene variants that segregate 
with exceptional longevity, which have been revised using 
a meta-analysis approach (113). Strength and limitations 
of the most powerful and used tools, such as genome-wide 
association study (GWAS) and whole-genome sequencing, 
have been recently reviewed by Giuliani et al. (114). The 
major results of this approach suggest that the genetics of 
longevity is highly population specific; small-effect alleles, 
pleiotropy, and the complex allele timing likely play a 
major role; and a close relationship between genetics of 
longevity and genetics of age-related diseases (including 
cardiovascular diseases) do exist. One important aspect 
in this as in other fields of research is reproducibility of 
the data. Some loci, such the one at chromosome 5q33.3, 
failed to show association in a replication analysis (115), 
while mutations located near APOE/TOMM40 have been 
replicated (116, 117, 118, 119) and confirmed in GWAS at 
genome-wide significance (115, 120, 121, 122). The e2e2 
or e2e3 genotype is associated with significantly increased 
odds to reach extreme longevity, whereas the APOEe4 
allele is thought to contribute to morbidity and earlier 
and higher mortality (123).
Translation to therapy of promising genes 
emerging from GWAS
APOE4-targeted therapeutic approaches that have been 
developed in animal models of Alzheimer disease and 
myocardial ischemia and are close to be translated to 
humans (124). ApoE is a ligand for low-density lipoprotein 
LDL receptors, plays a role in lipid metabolism, and is 
pathogenically implicated in cardiovascular diseases. 
For instance, apoE4 can affect cerebrovascular integrity 
by several mechanisms, one of which consists of the 
accumulation of Aβ in the cerebral vasculature. Potential 
therapies targeting ApoE comprise of silencing the gene 
by CRISP/Cas9 editing, anti-ApoE4 immunotherapy, 
structure correction or degradation, or use of molecules 
interacting with the protein or related signaling.
A GWAS performed on an Italian set of long living 
individuals (LLIs) and controls identified the BPI Fold-
Containing Family B member 4 (BPIFB4) gene to be 
associated with lifespan, a result validated on two 
independent populations from Germany and USA (125). 
The minor allele rs2070325 is part of a SNP haplotype that 
codifies for a wild type variant (WT), a longevity-associated 
variant (LAV), and a rare variant (RV) of BPIFB4. The 
levels of immunoreactive BPIFB4 protein are reportedly 
higher in plasma and hematopoietic cells of healthy 
LLIs compared with diseased LLIs or young controls 
(126, 127). Overexpression of LAV-BPIFB4 induced the 
activation of stress response-related heat-shock proteins, 
improved proteostasis, and increased nitric oxide 
availability in human cells (125). Studies in experimental 
models of cardiovascular disease showed that viral-
vector mediated transfer of the human LAV-BPIFB4 gene 
attenuates hypertension, atherosclerosis, and ischemic 
disease (125, 128, 129, 130, 131). Preclinical results on 
BPIFB4 gene therapy provides compelling experimental 
evidence for the potential of transferring the healthy 
features of centenarians to individuals at risk. A major 
concept emerging from studies using LAV-BPIFB4 is that 
gene transfer modified the molecular landscape without 
reversing it to that of normal controls. This is in keeping 
with the fact that centenarians experience age-related 
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diseases but cope better with them, possibly through 
amplification of unconventional molecular mechanisms 
able to override the pathological process. Clinical studies 
confirming safety and efficacy will determine if this 
novel modality may have a disruptive impact on current 
therapeutic modalities
Lessons from genetics of restricted lifespan
The Hutchinson–Gilford Progeria Syndrome (HGPS), 
a fast aging disorder, is characterized by an increased 
risk of atherosclerosis-induced complications, such as 
heart attack and stroke (132). The phenotypic effects are 
brought about by the mutation-induced expression of the 
progerin protein, a truncated splice variant of the nuclear 
architectural lamin A (132). This protein plays a role in 
nuclear structural stability and other nuclear functions 
such as DNA replication, DNA repair, and chromatin 
and nuclear pore complex organization. Maturation 
and stabilization of lamin A requires the cleavage of the 
farnesylated C-terminus by a zinc metalloprotease. Due to 
aberrant splicing, the lamin A variant progerin is truncated 
and remains stuck in its immature form. This leads to 
delocalization of nuclear envelope proteins, disorganized 
heterochromatin and nuclear pore complexes, disrupted 
nuclear morphology, and increased DNA damage and 
repair. Cells affected by progerin expression have increased 
nuclear rigidity and are more sensitive to mechanical 
strain. Phenotypic symptoms of HGPS are especially 
seen in tissues with high levels of mechanical stress such 
as bone, skeletal muscle, the heart, and blood 
vessels (132, 133).
Interestingly, progerin is not only present in the 
cases of HGPS patients, being also expressed in healthy 
aging individuals though to a lesser degree. This stands 
to reason that some of the modalities used to treat HGPS 
might be replicated or adapted to combat age-associated 
cardiovascular regenerative decline (134, 135). Progerin 
activates and dysregulates various downstream of Notch, 
including HES1, HES5, and HEY (135). It was therefore 
suggested that using inhibitors of the Notch signaling 
pathway could be a viable option to combat cardiovascular 
aging (135, 136). Recovery from an ischemic insult requires 
the activation of inflammatory cells and vascular cells and 
timely resolution of the initial sterile inflammation. In a 
murine model, we showed that targeting the Dll4/Notch 
signaling could have a relevant impact on coordinating 
reparative angiogenesis and inflammation under ischemic 
conditions (137).
More than 70% of UK adults aged 25 and over have low 
vitamin D levels. This can have an impact on precocious 
senescence. In fact, it was shown that HGPS cells have 
reduced expression of vitamin D receptor (VDR), and that 
reconstituting VDR signaling via 1α,25-dihydroxyvitamin 
D3 treatment alleviates HGPS phenotypes, including 
nuclear morphological abnormalities, DNA repair defects, 
and premature senescence (138). Interestingly, vitamin D 
supplementation delayed epigenetic aging in overweight 
and obese non-HGPS individuals with suboptimal 
vitamin D status (139). Therefore, supplementation of 
this nutrient can be a viable method to improve health 
span in the general population. 
Taking a closer look at the mechanisms by which 
progerin may be linked to physiological aging has revealed 
another mode of treatment (140). Progerin mRNA levels 
and levels of progerin do not increase with age; therefore, 
the hallmarks of aging are not related to an accumulation 
of progerin over time (140). Rather, the presence and 
expression of progerin mRNA in the nucleus leads to 
the delocalization and accumulation of wild type lamin 
A at the nuclear rim (140). In vivo, targeting the cryptic 
splice site in the gene with a morpholino oligonucleotide 
(Exo11) via electroporation of affected cells reversed the 
aberrant cellular phenotypes (140, 141).
Conclusions
Evidence form the literature highlights the complex 
molecular machinery involved in the dysregulation of 
cardiovascular function with aging. Investigation of 
mechanisms that allow the maintenance of health during 
aging or inhibit genetic programs of premature senescence 
could provide novel therapeutic modalities superior to 
current treatments. Much more research, refinement, and 
preclinical testing are, however, required before these 
treatments enter the clinical stage.
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